The global healthcare landscape is fraught with quality, cost, equity, and innovation challenges. Despite this, successful healthcare interventions have emerged from unexpected locations. In India, the eradication of certain communicable diseases, the expansion of access to primary care, and the implementation of innovative methods such as telemedicine have demonstrated the potential for community-centered care. In the United States (US), improvements in healthcare quality, accessibility, and the utilization of medical technology, such as the incorporation of telehealth and artificial intelligence, have highlighted opportunities for technological innovation in healthcare delivery. This manuscript reviews the history and development of healthcare systems in India and the US, highlighting each system's strengths, weaknesses, lessons learned, and opportunities for improvement. By examining both systems, we strive to promote a healthcare model that incorporates lessons from each country to improve community-centered care and ultimately provide equitable access to all.

Background: Multiple randomized controlled trials (RCTs) have investigated the impact of adding checkpoint inhibitors to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC) patients. However, there is a lack of biomarkers that can help identify patients who would benefit from combination therapy. Our research identifies response predictors and assesses the effectiveness of adding immunotherapy to neoadjuvant chemotherapy for TNBC patients. Methods: We identified eligible RCTs by searching PubMed, Cochrane CENTRAL, Embase, and oncological meetings. For this meta-analysis, we obtained odds ratios using the standard random effects model. To assess the heterogeneity of the study outcomes, the I2 statistic was obtained. Potential bias was assessed using a funnel plot and the corresponding Egger’s test. Results: In total, 1637 patients with TNBC were included from five RCTs. Neoadjuvant chemoimmunotherapy significantly improved pCR when compared to neoadjuvant chemotherapy alone. In the subgroup analysis, neoadjuvant chemoimmunotherapy showed higher pCR rates in both Programmed death-ligand 1 (PD-L1)-positive and PD-L1-negative TNBC patients. An Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0 correlated with increased pCRs (OR = 1.9, p < 0.001) in neoadjuvant chemoimmunotherapy vs. neoadjuvant chemotherapy, but no benefit was observed for patients with ECOG PS 1. Nodal positivity was significantly associated with pCR (OR = 2.52, p < 0.001), while neoadjuvant chemoimmunotherapy did not benefit patients with negative lymph nodes. Conclusions: Checkpoint inhibition and neoadjuvant chemotherapy significantly increased pCRs in TNBC patients, regardless of their PDL-1 status. Additional checkpoint inhibitors improved pCR rates, mainly for patients with ECOG PS 0 and lymph node-positive disease.

Immunoglobulin A vasculitis (IgAV), formerly Henoch-Schönlein purpura (HSP), is a small-vessel vasculitis with IgA (immunoglobulin A) immune complex deposition that predominantly affects the skin, joints, kidneys, and gastrointestinal (GI) tract. While less common in adults than in children, IgAV (immunoglobulin A vasculitis) is more severe and less well-characterized in adults. GI involvement in adults is associated with significant morbidity, motivating a comprehensive understanding of IgAV pathophysiology, diagnosis, and management. We synthesized current literature on adult IgAV with GI involvement, including its epidemiology, immune mechanisms, genetic drivers, diagnostic approaches, treatment modalities, and prognostic factors. The pathogenesis of IgA vasculitis involves immune complex-mediated small-vessel inflammation driven by aberrant IgA responses, proinflammatory cytokines, genetic predisposition, and environmental triggers. GI involvement occurs in 37-65% of adult IgAV cases, with symptoms ranging from abdominal pain and hematochezia to severe complications such as perforation and ischemia. Diagnosis relies on measurement of laboratory markers (elevated C-reactive protein, Neutrophil-to-Lymphocyte ratio, D-dimer) and imaging (computed tomography, endoscopy). Treatment includes corticosteroids for moderate-to-severe cases, with immunosuppressants (mycophenolate mofetil, intravenous immunoglobulins) reserved for refractory cases. Surgical intervention is rare but necessary in cases of life-threatening complications. Prognostic factors include age, renal involvement, and genetic markers. Adult GI IgAV requires early recognition and a multidisciplinary approach for effective management. Future research should explore advanced biomarkers and therapeutic strategies to improve outcomes.

Background: Hypoxic hepatitis (HH), also termed ischemic hepatitis and historically described as shock liver, is an acute liver injury syndrome in critically ill patients characterized by a rapid and marked rise in aminotransferases in the setting of circulatory, cardiac, or respiratory failure, after exclusion of other causes of acute hepatic injury. Despite its clinical relevance, the true incidence and prognostic significance of HH remain unclear. This systematic review and meta-analysis aimed to determine the pooled incidence, mortality, and outcomes of HH in critically ill patients. Methods: This study followed PRISMA guidelines and was registered in PROSPERO (CRD420251088120). A systematic search of PubMed, Scopus, Web of Science, EMBASE, Cochrane, LILACS, CNKI, and Google Scholar was conducted on July 4, 2025. Randomized, cohort, and case-control studies involving critically ill adults were included. Primary outcomes were HH incidence and mortality; secondary outcomes included length of stay, organ support, and comparisons with non-HH patients. Random-effects meta-analyses were performed, with heterogeneity assessed using I ² statistics. Results: Of 3236 records, 25 studies (150,928 patients) met inclusion criteria. The pooled prevalence of HH in ICU patients was 8.3%, and all-cause mortality was 64.0%. Compared with non-HH patients, HH was associated with higher all-cause mortality (RR 2.94). Mechanical ventilation (RR 2.44) and renal replacement therapy (RR 3.80) showed elevated but statistically non-significant associations. Cardiogenic shock, cardiac arrest, and sepsis were the leading reported precipitants. Conclusion: HH affects a substantial proportion of ICU patients and is consistently associated with adverse outcomes and greater organ support use. However, the available evidence supports HH primarily as an associated prognostic marker rather than a proven causal determinant of mortality. Findings should be interpreted cautiously because of high heterogeneity, potential residual confounding, and possible publication bias. Standardized diagnostic criteria and prospective studies evaluating incremental prognostic value beyond established ICU severity scores are needed.

Background: Hypoxic hepatitis (HH), also termed ischemic hepatitis or shock liver, is an acute hepatocellular injury caused by an imbalance between hepatic oxygen supply and demand. It develops secondary to cardiac, circulatory, or respiratory failure through reduced hepatic blood flow, systemic hypoxemia, hepatic venous congestion, or impaired cellular oxygen utilization. Although its recognition in critical care has increased, the clinical and biochemical factors distinguishing survivors from non-survivors remain poorly defined. This analysis aimed to characterize these differences among critically ill adults diagnosed with HH. Methods: This systematic review and meta-analysis followed PRISMA guidelines and was pre-registered in PROSPERO (CRD420251180238). A comprehensive search of PubMed, Scopus, Web of Science, EMBASE, Cochrane, LILACS, CNKI, CINAHL, and Google Scholar was conducted on July 4, 2025. Eligible studies included critically ill patients diagnosed with HH. Random-effects meta-analyses were performed in R. Results: Of 3236 identified records, five cohort studies comprising 107,346 participants were included. The pooled mean difference in age between survivors and non-survivors was −5.1 years (p = 0.03; I ² = 23.1%). Mechanical ventilation was associated with lower survival (RR = 0.76; p < 0.01; I ² = 0.7%), and norepinephrine or other hemodynamic support was associated with lower odds of survival (OR = 0.4; p < 0.01; I ² = 5.5%). In contrast, lactate, bilirubin, and INR were not significantly associated with survival. Conclusion: Hypoxic hepatitis should be interpreted primarily as a secondary marker of severe cardiac, circulatory, or respiratory failure rather than as an isolated primary driver of mortality. Its occurrence may be associated with increased mortality in critically ill patients; however, the available evidence is limited by the small number of eligible studies and heterogeneity. Further standardized, prospective studies are needed to clarify its independent prognostic significance.